Search

Displaying results 1251 - 1260 of 2674 in total
  1. Drug

    Tobramycin

    go.drugbank.com/drugs/DB00684
    ApprovedInvestigational

    [A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to

  2. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Panthenol exists as a racemic mixture containing both the dextrorotatory form ...

  3. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … Casimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent

  4. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  5. Target

    6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1

    go.drugbank.com/bio_entities/BE0001073
    TargetEnzymeHumans

    Synthesis and degradation of fructose 2,6-bisphosphate

    Synonyms: 6PF-2-K/Fru-2,6-P2ase 1, 6PF-2-K/Fru-2,6-P2ase liver isozyme
  6. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    [A177637] The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]

  7. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located

  8. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

  9. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub

    Categories: Angiotensin 2 Receptor Blocker, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  10. Target

    NADPH-flavin oxidoreductase

    go.drugbank.com/bio_entities/BE0002629
    TargetVibrio harveyi

    Catalyzes the NADPH-dependent reduction of FMN to FMNH(2). Involved in bioluminescence by providing FMNH(2) to luciferase.

    Synonyms: FRP